Author: digi

Expanded Access and Compassionate Use Programs in Phase 4 Clinical Trials

June 4, 2025

Expanded Access and Compassionate Use Programs in Phase 4 Clinical Trials How Phase 4 Trials Enable Expanded Access and Compassionate Use for Life-Saving Therapies Introduction: Bridging Urgent Medical Needs with Unapproved Therapies In certain life-threatening or rare conditions, patients may exhaust all approved treatment options while new drugs are still under regulatory review or in…

Phase 4 (Post-Marketing Surveillance)

Commercial Planning and Market Access Strategy After Phase 3 Trials: A Practical Guide for Global Launch Success

June 4, 2025

digi

Commercial Planning and Market Access Strategy After Phase 3 Trials: A Practical Guide for Global Launch Success How to Plan Commercialization and Ensure Market Access After Phase 3 Trials Why Commercial Planning Begins After Phase 3 Once a Phase 3 clinical trial successfully demonstrates safety and efficacy, attention shifts to commercial readiness. Bringing a product…

Phase 3 (Confirmation and Monitoring)

Implementing Interim Analyses in Adaptive Trials – Clinical Trial Design and Protocol Development

June 4, 2025

digi

Implementing Interim Analyses in Adaptive Trials – Clinical Trial Design and Protocol Development “Conducting Temporary Evaluations in Adjustable Trials” Introduction to Interim Analyses in Adaptive Trials Implementing interim analyses in adaptive clinical trials is a critical component of the trial process. Interim analyses are evaluations of trial data performed at pre-specified times during the data…

Adaptive Trial Designs, Clinical Trial Design and Protocol Development

Bayesian Approaches in Phase 2 Designs

June 4, 2025

digi

Bayesian Approaches in Phase 2 Designs Applying Bayesian Methods in Phase 2 Clinical Trial Design Introduction Phase 2 clinical trials are a critical stage for evaluating preliminary efficacy, determining optimal dosing, and making go/no-go decisions. Increasingly, sponsors are turning to Bayesian statistical methods in Phase 2 designs to increase flexibility, incorporate prior knowledge, and optimize…

Phase 2 (Efficacy and Side Effects)

Placebo Control in Phase 1: When and Why It’s Used

June 4, 2025

digi

Placebo Control in Phase 1: When and Why It’s Used Understanding the Role of Placebos in Phase 1 Clinical Trial Designs Introduction In Phase 1 clinical trials—especially first-in-human studies—the primary goal is to evaluate the safety, tolerability, pharmacokinetics (PK), and sometimes pharmacodynamics (PD) of an investigational drug. While efficacy is not the main objective at…

Phase 1 (Safety and Dosage)

Adherence and Compliance Studies in Phase 4 Clinical Trials: Real-World Challenges and Strategies

June 4, 2025

digi

Adherence and Compliance Studies in Phase 4 Clinical Trials: Real-World Challenges and Strategies Improving Patient Adherence and Compliance Through Phase 4 Research Why Adherence Matters Post-Approval Clinical trial results often assume optimal patient behavior. However, in the real world, the true impact of a drug depends on whether patients take it consistently and correctly. Non-adherence…

Phase 4 (Post-Marketing Surveillance)

Regulatory Guidelines on Adaptive Designs (FDA, EMA) – Clinical Trial Design and Protocol Development

June 4, 2025

digi

Regulatory Guidelines on Adaptive Designs (FDA, EMA) – Clinical Trial Design and Protocol Development “Adaptive Design Regulations as per FDA and EMA Guidelines” Introduction Adaptive designs are a crucial component of clinical studies, allowing for modifications to the trial after it commences without undermining the validity and integrity of the study. Two primary regulatory bodies,…

Adaptive Trial Designs, Clinical Trial Design and Protocol Development

Post-Approval Commitments and Phase 4 Study Planning After Phase 3 Trials: A Complete Guide

June 4, 2025

digi

Post-Approval Commitments and Phase 4 Study Planning After Phase 3 Trials: A Complete Guide How to Plan Post-Marketing Studies and Fulfill Regulatory Commitments After Phase 3 Trials What Happens After Phase 3 Approval? Approval after successful Phase 3 trials isn’t the end—it’s the beginning of a new chapter in clinical development. Regulatory agencies may grant…

Phase 3 (Confirmation and Monitoring)

Sample Size Calculation for Phase 2 Trials

June 4, 2025

digi

Sample Size Calculation for Phase 2 Trials How to Calculate Sample Size for Phase 2 Clinical Trials Introduction Determining the appropriate sample size in a Phase 2 clinical trial is a critical step that directly affects the trial’s ability to detect meaningful treatment effects, avoid underpowered results, and prevent unnecessary exposure of patients to experimental…

Phase 2 (Efficacy and Side Effects)

Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment

June 4, 2025

digi

Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment Designing Biosimilar Phase 1 Trials: PK, PD, and Immunogenicity Considerations Introduction Biosimilars—biologic products that are highly similar to an approved reference product—must undergo rigorous evaluation to demonstrate similarity in structure, function, and clinical performance. Phase 1 clinical trials are a cornerstone of biosimilar development and…

Phase 1 (Safety and Dosage)